Literature DB >> 12607570

Behaviour of insomniacs and implication for their management.

Eduard Estivill1.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12607570     DOI： 10.1016/s1087-0792(02)80001-6

Source DB:  PubMed          Journal:  Sleep Med Rev        ISSN： 1087-0792            Impact factor:   11.609


× No keyword cloud information.
  4 in total

1.  Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.

Authors:  Thomas Roth; Steven G Hull; D Alan Lankford; Russell Rosenberg; Martin B Scharf
Journal:  Sleep       Date:  2008-09       Impact factor: 5.849

2.  Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study.

Authors:  Thomas Roth; Andrew Krystal; Frank J Steinberg; Nikhilesh N Singh; Margaret Moline
Journal:  Sleep       Date:  2013-02-01       Impact factor: 5.849

3.  Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.

Authors:  Andrew D Krystal; Milton Erman; Gary K Zammit; C Soubrane; Thomas Roth
Journal:  Sleep       Date:  2008-01       Impact factor: 5.849

4.  Efficacy and safety of as-needed, post bedtime dosing with indiplon in insomnia patients with chronic difficulty maintaining sleep.

Authors:  Thomas Roth; Gary K Zammit; Martin B Scharf; Robert Farber
Journal:  Sleep       Date:  2007-12       Impact factor: 5.849
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.